Development of Second Messenger, Trafficking, and Functional Assays for GPR119

GPR119 第二信使的开发、贩运和功能分析

基本信息

项目摘要

DESCRIPTION (provided by applicant): The G protein coupled receptor GPR119 is a recently deophanized receptor that has emerged as an attractive target for the treatment of obesity and Type 2 Diabetes Mellitus. Recent studies in animal models have demonstrated that activation of GPR119 improves glucose homeostasis while positively modulating both food intake and weight gain. It is expressed predominantly in the pancreas and gut of humans and rats and in rodent brain. Activation of GPR119 promotes secretion of the incretin GLP1 from intestinal L cells and insulin from pancreatic beta cells, both key components in regulating glucose homeostasis. Small molecule modulators of GPR119 have recently been reported however, these molecules differ with respect to their signaling properties and insulin secretion from the endogenous ligand Olethylethanolamide (OEA), rendering them unsuitable probes for the interrogation of GPR119 biology and function. The emphasis of this application is on developing innovative and novel assays for GPR119 that are HTS compatible, secondary screening assays to triage artifacts, counterscreens to assess selectivity of compounds versus two structurally related GPCRs and functional assays to elucidate pharmacology of compounds in physiologically relevant cell types to assess in vitro efficacy for promoting incretin and insulin secretion. These assays are designed to be the cornerstone for the discovery of novel small molecule probes to be used in the exploration of GPR119 biology and function. PUBLIC HEALTH RELEVANCE: The GPR119 receptor is expressed in the pancreas and gastrointestinal tract and has recently emerged as an attractive target for the treatment of obesity and Type 2 Diabetes Mellitus. This proposal seeks to develop a series of novel high throughput compatible cell-based functional assay to identify GPR119 selective ligands that can be used as molecular probes to interrogate GPR119 receptor function in normal physiological processes and disease states.
描述(由申请人提供):G蛋白偶联受体GPR119是一种最近被去蛋白化的受体,已成为治疗肥胖和2型糖尿病的一个有吸引力的靶点。最近在动物模型中的研究表明,激活GPR119可以改善葡萄糖稳态,同时积极调节食物摄入和体重增加。它主要在人类和大鼠的胰腺和肠道以及啮齿动物的大脑中表达。GPR119的激活促进肠L细胞分泌肠促胰岛素GLP1和胰腺β细胞分泌胰岛素,这两者都是调节葡萄糖稳态的关键成分。最近已经报道了GPR119的小分子调节剂,然而,这些分子在其信号特性和内源性配体油乙基乙醇酰胺(OEA)的胰岛素分泌方面存在差异,这使得它们不适合用于探究GPR119的生物学和功能。该申请的重点是开发与HTS兼容的GPR119的创新和新颖的分析方法,用于分类伪产物的二次筛选分析,用于评估化合物与两种结构相关的gprcrs的选择性的反筛选,以及用于阐明生理相关细胞类型中化合物的药理学的功能分析,以评估促进肠促胰岛素和胰岛素分泌的体外功效。这些检测被设计为发现用于探索GPR119生物学和功能的新型小分子探针的基石。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patricia Helen McDonald其他文献

Patricia Helen McDonald的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patricia Helen McDonald', 18)}}的其他基金

A High Content Screening Platform for High Throughput, High Content Imaging and Analysis
用于高通量、高内涵成像和分析的高内涵筛选平台
  • 批准号:
    10431416
  • 财政年份:
    2022
  • 资助金额:
    $ 41.12万
  • 项目类别:
Assay Development for Substrate and Phosphorylation State Specific JNK Inhibitors
底物和磷酸化状态特异性 JNK 抑制剂的检测开发
  • 批准号:
    8910762
  • 财政年份:
    2013
  • 资助金额:
    $ 41.12万
  • 项目类别:
Development of Chemical Probes to Investigate the Role of NTSR1 in CNS Disorders
开发化学探针来研究 NTSR1 在中枢神经系统疾病中的作用
  • 批准号:
    8082595
  • 财政年份:
    2010
  • 资助金额:
    $ 41.12万
  • 项目类别:
Development of Chemical Probes to Investigate the Role of NTSR1 in CNS Disorders
开发化学探针来研究 NTSR1 在中枢神经系统疾病中的作用
  • 批准号:
    7999145
  • 财政年份:
    2010
  • 资助金额:
    $ 41.12万
  • 项目类别:
Development of Second Messenger, Trafficking, and Functional Assays for GPR119
GPR119 第二信使的开发、贩运和功能分析
  • 批准号:
    7866783
  • 财政年份:
    2010
  • 资助金额:
    $ 41.12万
  • 项目类别:
Development of Second Messenger, Trafficking, and Functional Assays for GPR119
GPR119 第二信使的开发、贩运和功能分析
  • 批准号:
    8249918
  • 财政年份:
    2010
  • 资助金额:
    $ 41.12万
  • 项目类别:
In Vitro Screening Strategies
体外筛选策略
  • 批准号:
    8465866
  • 财政年份:
  • 资助金额:
    $ 41.12万
  • 项目类别:
In Vitro Screening Strategies
体外筛选策略
  • 批准号:
    8653563
  • 财政年份:
  • 资助金额:
    $ 41.12万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 41.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 41.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 41.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了